Introduction
Approximately 20% of colorectal cancer (CRC) cases are found to have distant metastasis at the time of diagnosis, and the 5-year survival rate is <8%. 1 The most common metastasis sites of CRC are the liver, lung, and peritoneum, but other metastatic sites have been described, such as bone, spleen, brain, and distant lymph nodes. [2] [3] [4] A nationwide retrospective review from 3,827 autopsies generated insight into the metastatic patterns and demonstrated that primary cancers tend to metastasize differently with different frequencies to distinctive sites. 2, 4, 5 Patients with rectal cancer more often metastasize to extra-abdominal sites, whereas colon cancer patients show a higher frequency of abdominal metastasis according to the pathological records of CRC patients. 5 It is well known that the most common metastatic site for CRC patients is the liver, followed by the lung. [2] [3] [4] However, the incidence of brain metastasis (BM) is very low (1.2%-3.2%) [6] [7] [8] [9] and is of most concern because of neurological symptoms. Additionally,
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Yang et al CRC with BM typically occurs at a later stage of disease progression. However, data regarding BM occurrence at the diagnosis of CRC are rare. It has been reported that cases with uncommon metastases, including BM, are increasing. 7 However, the overall survival (OS) of advanced CRC has been improving due to treatment progression. Cytotoxic agents and targeted therapies have improved the prognosis of unresectable CRC patients up to 30 months. 10 Currently, the advancement of immunotherapy has markedly improved the prognosis of mismatch-repair deficient (microsatellite instability-deficient) cohort of CRC. 11 Multidisciplinary treatments could be applied for the treatment of metastatic lesions, including the BM. 12 Therefore, early diagnosis of BM is of vital importance. Unfortunately, the risk factors associated with the initial diagnosis of BM have not yet been fully investigated due to the limited number of patients.
It has been observed in clinical trial follow-ups that mucinous adenocarcinomas (MCs) have different distribution of metastatic disease compared with the more common adenocarcinoma (AC). Right-sided colon cancer (RCC) occurs in ~10%-15% of CRC cases. RCC has often been considered a distinct entity, consisting of characteristics similar to MC with a poor prognosis in metastatic disease. [13] [14] [15] However, whether these clinical factors contribute differently to BM in CRC remains unknown.
The purpose of the present study was to use the Surveillance, Epidemiology, and End Results (SEER) database to characterize the incidence of BM at the time of CRC diagnosis and examine if BM diagnosis is a risk factor for the prognosis of CRC. In addition, we sought to examine the clinical and sociodemographic predictors of poor survival among patients with BM at CRC diagnosis.
Patients and methods
Data regarding BM at the time of initial cancer diagnosis were retrieved from cases after 2010 in the SEER program of the National Cancer Institute SEER database. The data sets are available in the SEER data set repository https:// seer.cancer.gov/ and could present information on 30% of the US population.
The TNM stage was recorded as the SEER's "extent of disease" (for T and M stage) and the "number of positive nodes" (for N stage) coding schemes. Pathology was grouped as AC, MC, or other. Tumor grade was classified as well differentiated, moderately differentiated, poorly differentiated, or undifferentiated. Patients were stratified by CRC subtype, including RCC (cecum, ascending colon, hepatic flexure, and transverse colon), left-sided colon cancer (LCC; splenic flexure, descending colon, and sigmoid colon), rectosigmoid cancer (RSC; rectosigmoid junction and rectum), and appendix cancer. 16 Race/ethnicity was categorized as previously described. Data on the presence of bone, lung, and liver metastases at diagnosis were available in the SEER database and were categorized as the extent of extracranial metastasis among patients in our study.
Patients were observed after their first diagnosis of CRC until the last follow-up, death, or end of the study, whichever occurred first.
Therefore, we included patients from 2010 to 2013, and patients who were proven to have BM 6 months after the diagnosis of CRC or were proven dead by autopsy were excluded. Thus, there were 170,793 patients diagnosed with CRC who were included in our analysis. Of these CRC patients, 401 were diagnosed with BM.
statistical analysis
Multivariable logistic regression was used to determine which characteristic was associated with the presence of BM at diagnosis among CRC patients or the M1 cohort. Multivariable Cox regression was performed to identify the covariates associated with poor survival. The Kaplan-Meier method was used to estimate the survival difference between the subgroups. Two-sided P<0.05 was considered statistically significant. Statistical analysis was performed using SAS 9.2 (SAS Institute, Cary, NC, USA).
ethics approval and consent to participate
As the data used were from SEER data set, which is publicly available; ethics approval and consent to participate are not applicable. 
Results
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Brain metastasis in newly diagnosed CRC Among the entire cohort, 401 patients presented with BM, reflecting 0.23% of the entire study population and 1.3% of the subset with metastatic disease at any site. Incidence proportions were highest among patients with RCC (0.2% of the entire cohort, 1.3% of the metastatic subset) and RSC (0.3% of the entire cohort, 1.5% of the metastatic subset) subtypes.
Also, 3.4% of the CRC patients with bone metastasis presented with BM at diagnosis, which was higher than that of liver or lung metastasis. Additionally, incidence proportions increased with extracranial metastatic sites (6.6% for ≥3, 2.2% for 2, 0.7% for 1, and 0.1% for 0). Interestingly, patients with liver metastasis demonstrated a low incidence rate (0.4%) of BM.
Multivariable logistic regression
On multivariable logistic regression ( associated with a higher risk of BM at CRC diagnosis using the multivariable model (Table 2) .
Survival
The median survival among patients with BM (with metastasis to other organs) at diagnosis was 7.0 months ( Figure 1A ). As shown in Figure 1B , the median survival was 15.59 months (range 11.60-19.59 months) for patients with BM merely without metastasis to other organs ( Figure 1B ), which showed that patient prognosis could be improved if BM was diagnosed early. Then we compared survival difference of patients without metastasis, patients with BM only, patients with metastasis but without BM, and patients with metastasis including BM. Additionally, patients with multi-metastasis having shorter survival, and the reason maybe the BM as shown in Figure 1B (patients with metastasis without BM vs patients with metastasis including BM, P<0.001).
The median survival was 9.01, 10.26, 14.57, and 5 for RCC, LCC, RSC, and appendix cancer, respectively (Table 1 ). In the entire cohort of patients, RCC had the poorest survival and appendix cancer had the best survival (P<0.001; Figure 2A ). However, in patients diagnosed with BM, RCC had the best survival (P=0.002; Figure 2B ).
The multivariable Cox regression analysis of all patients is presented in Table 3 (Table 3) . OS estimates by the extent of extracranial metastatic disease is shown is Figure 2C , D. In general, survival was poorer among patients who displayed more extensive systemic disease at CRC diagnosis. However, this trend was merely significant in the cohort of extracranial systemic disease only (3 sites vs 2 sites, P<0.001; 2 sites vs 1 site, P<0.001; Figure  2E ) and was not found in the BM cohort (2 sites vs 1 site, P=0.559; 3 sites vs 2 sites, P=0.322; Figure 2F ). Table 4 displays the median survival by subtype as stratified by the extent of systemic disease in the cohort of extracranial systemic disease only and the cohort of extracranial systemic disease and BM. In addition, we found that the presence of BM at initial diagnosis was associated with a shorter survival time compared with patients who presented with de novo metastatic disease without baseline brain involvement (Table 4) .
Discussion
In the present study, the median OS for patients with BM (with metastasis to other organs) was 7 months, which was shorter than reported previously (14.5 months). 17 The median survival was 15 We demonstrated that tumor site, bone metastases, and more number of extracranial metastasis were associated with BM at CRC diagnosis. Sundermeyer et al reported that lung metastasis is a risk factor for BM; the incidence is higher in 
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Brain metastasis in newly diagnosed CRC Many studies have found that metastasis progresses sequentially in many patients, and that BM is one of the late sites of involvement. 20, 21 RCC showed more frequency of BM than any other tumor site among all the BM patients. Furthermore, we found that RCC was an independent risk factor of BM. Previous studies have shown that RCC may be a different entity from LCC, including differences in epidemiological, clinical, and molecular biological, and prognostic findings between RCC and LCC. [22] [23] [24] Additionally, we found that RCC had the poorest survival. However, when patients were diagnosed with BM, RCC patients had better survival than LCC patients and appendix cancer had the poorest survival. We are unsure of the mechanism of this phenomenon.
In addition, age and pathology type were independent factors in patients with BM at the diagnosis of CRC (in the whole cohort and the M1 cohort). Additionally, patients presenting with appendix tumors with BM, of age >70 years, and with MC showed the poorest survival. Age at the time of initial diagnosis was the variable that constantly revealed a significant effect on survival, suggesting a better performance status in younger patients. [25] [26] [27] [28] Major immune defects occur at an older age, including the lack of naïve T-cells, impaired activation pathways of T-cells, antigen-presenting cells, and age-related changes in the tumor microenvironment. Patients with MC showed poorer survival than patients with AC in CRC diagnosed with BM. The presence of metastatic disease in more than one location was more frequent in MC compared with AC. 5 In MC patients, we found a high rate of peritoneal metastases. Several clinical studies have suggested differences in metastatic patterns between histological subtypes. 13, 29, 30 Since curative surgery is an option that is mainly limited to liver metastases, this may be an explanation for the poor performance of MC patients in trials for metastatic disease. 13, 29 In the current study, the unadjusted probability of BM was calculated as 3.4% for CRC metastases. The incidence of BM has increased as much as 3% since recent extended treatment options have been made available, which have caused an improvement in advanced CRC prognosis. 7 Therefore, the potential of BM should be made aware to the clinicians, especially when patients present with RCC, have bone metastases, or more than three extracranial metastases. For such high-risk patients, brain scans may have to be considered.
Limitations of this study include its retrospective design, selection bias, and heterogeneous population. Furthermore, in the CRC patients, brain imaging was not routinely performed, except at the occurrence of symptoms, which may potentially underestimate the true positive rate of BM. In addition, our patients were not analyzed for the effects of gene mutation in BM tumors at the initial diagnosis, although a recent study demonstrated that RAS-or PIK3CA-mutant CRC patients were more likely to develop BM. 
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In this study we found that RCC, MC, bone metastases, and more than three extracranial metastases were independent predictors of BM in CRC patients. People with BM without metastasis to other organs had relatively better survival than BM patients with metastasis to other organs. So, it is important to improve available therapeutic options to enhance quality of life, especially for the people with BM without metastasis to other organs.
Data sharing statement
All data were retrieved from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute between 2010 and 2012. The data sets are available in the SEER data set repository https://seer.cancer.gov/.
